William Spreen

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

Raphael J. Landovitz, Deborah Donnell, Meredith E. Clement et al. · New England Journal of Medicine · 2021 · 853 citations · Full text

Public Health, Infectious Diseases, Pharmacotherapy +16

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

Seth Hetherington, Arlene R. Hughes, Michael Mosteller et al. · The Lancet · 2002 · 812 citations

Life Sciences, Genetics, Molecular Genetics +15

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

Susan Swindells, Jaime Andrade‐Villanueva, Gary Richmond et al. · New England Journal of Medicine · 2020 · 565 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial

Sinéad Delany‐Moretlwe, James P. Hughes, Peter Bock et al. · The Lancet · 2022 · 540 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

David A. Margolis, Juan González‐García, Hans-Jürgen Stellbrink et al. · The Lancet · 2017 · 504 citations

Medicine, Pharmacology, Pharmacotherapy +14